Biotechnology and the American Media: The Policy Process and the Elite Press, 1970-1999 by Nisbet, Matthew C. & Lewenstein, Bruce V.
    
IN PRESS: SCIENCE COMMUNICATION June 2002, 23(4): 259-391 
 
Biotechnology and the American Media: 
The Policy Process and the Elite Press, 1970 to 1999 
 
Matthew C. Nisbet* 
Bruce V. Lewenstein 
Media and Society Research Group 
Department of Communication 
Cornell University 
338 Kennedy Hall 
Ithaca, NY 14853 
Nisbet phone: 607.269.3287; e-mail: mcn23@cornell.edu 
Lewenstein phone: 607.255.8310; e-mail: bvl1@cornell.edu 
 
 
KEYWORDS: Media coverage of biotechnology; biotechnology policy; frame building; agenda 
building. 
 Biotech and the Elite Press, 1970 to 1999  - 2 - 
 
 
BIOTECHNOLOGY AND THE AMERICAN MEDIA: 
The Policy Process and the Elite Press, 1970 to 1999 
 
 In this paper, we present a quantitative content analysis of biotechnology-related 
coverage appearing in the New York Times and Newsweek between the years 1970 to 1999, 
examining patterns of media attention and evaluating the source impact of various political and 
social actors on the themes, frames, and tone of coverage.  Although media attention to 
biotechnology steadily increased across the 1980s and for most of the 1990s, media attention 
within years has been highly episodic, peaking and plummeting in response to major scientific 
announcements or related focusing events.  Even in its peak years of coverage, biotechnology 
still rests rather modestly on the overall media agenda in comparison to other major political 
issues, and in comparison to other issues related to science, technology, or popular culture.  The 
character of biotechnology-related coverage has been overwhelmingly positive, and has been 
dominated by scientists, government actors, and industry, with a heavy emphasis on the frames 
of scientific progress and economic prospect.  A departure from this trend only occurs in 
correspondence to the late 1990s debate over cloning, as a greater media emphasis on ethics and 
controversy emerges.
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BIOTECHNOLOGY AND THE AMERICAN MEDIA: 
The Policy Process and the Elite Press, 1970 to 1999 
  
For several millennia, humans have been using biological technology, or 
“biotechnology,” to alter their surroundings and environment, embracing techniques including 
cheese making and brewing, as well as plant and animal breeding.  Only beginning in 1970 did a 
“new” biotechnology emerge, involving a more precise (and sometimes more powerful) direct 
manipulation of living organisms at the genetic level that has resulted in a diversity of 
applications.  Specific to the health sciences, examples of these applications include reproductive 
techniques like in vitro fertilization; research involving human embryos and stem cells; new and 
more potent biological weapons; research involving gene therapy and predictive medicine; as 
well as genetically engineered vaccines and pharmaceuticals.  Applications specific to 
agriculture involve novel or more resistant genetically modified plants and bacteria that over-
express or under-express a gene, or include new genes; and genetically-modified or cloned 
animals that are designed to increase food production, manifest desired traits, or serve as 
biofactories to produce pharmaceuticals and organ transplants.  The new biotechnology has even 
sparked debate and claims specific to human cloning, including the creation of vain self-replicas, 
the hoped for “resurrection” of a lost child, or the harvesting of organs and bone marrow from 
cloned tissue. 
Guiding these biotechnology-related advances have been the shared interactions between 
scientists, policymakers, industry, and other political or social interests (Cozzens and 
Woodhouse, 1995), with these actors engaged in a power game over control of biotechnology’s 
applications and benefits (Gaskell, Bauer, and Durant, 1998).  Indeed, modern biotechnology’s 
thirty year history has been inherently “political,” as development has taken place within the 
larger context of American policy-making, a process characterized by a  “pressure system” 
highly restricted to a few interests that often dominate political alternatives, with power 
emanating from the ability to define or frame issues (Shattschneider, 1960).  
The media have played an integral, interactive role within this political competition.  As 
we will review in this paper, the mass media comprise the principle arena where policy-relevant 
issues come to the attention of decision-makers, interest groups, and the public.  Not only do the 
media influence the attention of competing political actors and the public, but the media also 
powerfully shape how policy issues related to biotechnology are defined and symbolized.  
The nature of media coverage then becomes an important subject for study in relation to 
the historical development of biotechnology.  Yet, only a few systematic surveys of 
biotechnology-related media coverage in the American context have been carried out.  In this 
paper, to redress this gap, we present a quantitative content analysis of biotechnology-related 
coverage appearing in the New York Times and Newsweek between 1970 and 1999.  In our study, 
we measure the visible source impact of various social and political actors, the tone of coverage, 
the main themes or issues covered, the main frames featured, and compare these measures to key 
political and economic events.  In adopting this approach, our results are not only of interest to 
specialists studying the political and social history of biotechnology, but also of interest to 
researchers in media studies, sociology, or political science who share a more general focus on 
the media agenda-building and frame-building processes.   
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The Policy Process and the Press 
In America’s “mediated democracy,” the processes and events that take place in the 
policy sphere, and the groups that compete in the political system, are not only mirrored (or 
covered) in the media, but also shaped by the media.  In most cases, the media’s influence comes 
early on in the policy process, determining what issues will be addressed on the policy agenda1 
(Kingdon, 1984; Linsky, 1986).  At this early stage in the policy process, the best political 
strategy where the influence of decision-makers can be direct, is one in which an interest group 
manages to control the scale of conflict on an issue, keeping decision-making behind closed 
doors away from public or media attention (Bachrach and Baratz, 1970; Cobb and Elder, 1971), 
thereby managing conflict before it starts (Shattschneider, 1960).  At the root of these 
“nondecisions” or “uncontroversies” that are kept from public view are structural or cultural 
factors that suppress noticeable disagreement among policy actors (Bachrach and Baratz, 1970; 
Cozzens and Woodhouse, 1995).  Often the result is a “mobilization of bias,” or a pattern of 
policy outcomes that systematically and consistently benefit certain interests over others 
(Shattschneider, 1960; Bachrach and Baratz, 1970). 
If an interest can control media and public attention to an issue, then they have succeeded 
in controlling the media and public agenda.  Moreover, when an issue does appear in the media, 
if interests can define their stand as well as the alternatives available for discussion, then they 
have “framed” the situation in more winnable terms, delimiting the arguments the opposition can 
make, and screening them off from participation (Berkowitz, 1992). These media “frames” offer 
a central organizing idea or story line that provide meaning to an unfolding series of events, 
suggesting what the controversy is about, and the essence of an issue (Gamson and Modigliani, 
1987).  Frames also serve as working routines for journalists that allow journalists to quickly 
identify and classify information, packaging it for audiences.  These organizing devices are 
especially useful when journalists are thrust into unfamiliar territory.  Framing strategies, 
however, can lead to "pack journalism," with journalists adopting similar frames across coverage 
(Gitlin, 1980).  
Once an issue is framed or characterized early on in a debate by the media, it can be very 
difficult for policymakers to shift the image of the issue to another perspective (Linksy, 1986; 
Schön and Rein, 1994). Recognizing the importance of media coverage in influencing policy 
outcomes, various competing interests or political actors often lobby the media in order to shape 
the attention and emphasis of coverage in a way that marshals support for their positions.  Within 
this “media agenda-building” process (Berkowitz, 1992) and “media frame-building” process 
(Scheufele, 1999), competing interests operate as news sources, supplying strategically packaged 
news items and story information to journalists.  Indeed, most stories are source generated 
(Gandy, 1982), with some estimates placing half or more of newspaper stories as source 
originated (Sigal, 1973; Soloski, 1989).   
Not only is news likely to be source driven and source framed, but certain types of 
interests are likely to be more influential in controlling and framing news than others.  In general, 
government affiliated interests are most effective at influencing news, often because their actions 
are considered newsworthy events. Journalists also come to rely on policy makers for “routine 
channel” information, or news that fits organizational deadlines or demands (Tuchman, 1978).  
Often this type of news is based on press conferences, press releases, or official proceedings 
(Sigal, 1973).  
Another type of influential source is industry.  By providing the media with expensive 
information subsidies—including video releases, well-crafted Web sites, and materials produced 
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by public relations professionals—industry interests are often able to make it easier for 
journalists to file their story on-time and efficiently (Berkowitz, 1992). Industry may also rely on 
paid direct media access in the form of political advertisements, or through the direct financial 
support of independent think tanks that produce experts used as objective sources (Danielan, 
1992).  Other sources—including lawyers, doctors, celebrities, and scientists—wield media 
influence because of their strategic location in the social or economic structure, and their 
perceived social legitimacy (Cobb and Elder, 1961). Over the last fifteen years, consumer, 
environmental, and “public interest” organizations have increasingly become more 
professionalized and hierarchical, adopting tactics similar to industry, including paid political 
ads, in-house experts, and public relations professionals (Lichter and Rothman, 1999).  However, 
their still limited resources in comparison to industry force these groups to rely more heavily on 
personal contacts in the media (Danielian, 1992). 
Competing interests frame issues in ways that strategically advantage their political 
positions, emphasizing certain aspects of an issue over other considerations, influencing 
estimations of the causes, consequences, and solutions to a policy problem.  If news coverage is 
heavily source dependent, and a few sources are advantaged in the competition to shape media’s 
agenda and frames, then the character of news coverage of any one issue is likely to be limited in 
scope and focus to the selective framing provided by the sources on which journalists most 
heavily depend (Miller and Reichert, 2000).  For most interests, their final goal is to make their 
perspective appear to be “official policy” in news coverage.  By successfully triggering such 
processes as a spiral of silence whereby voices of dissent are increasingly driven out of news 
coverage in deference to a perceived majority perspective (Noelle-Neumann, 1984; Scheufele 
and Moy, 1999) hegemonic media coverage can result. This state of hegemony is characterized 
by media coverage that constructs only one viewpoint as legitimate, or media coverage that 
heavily delegitimizes dissenting perspectives (Gitlin, 1980; Hallin; 1987; Miller and Reichert, 
2000). 
Examples related to biotechnology. Several historical accounts of biotechnology have 
characterized the influence of sources on the media agenda-building and frame-building 
processes.  In one case, during the Recombinant DNA (rDNA) debates of the early 1970s, when 
scientists first called attention to possible risks associated with rDNA technology, they framed 
the issue in a series of public letters to Science as a narrow question of laboratory-based technical 
risk, best resolved as an internal matter among scientists.  At the 1975 Asilomar conference, 
scientists convened debate behind closed doors, issued tight controls on media reports (Rogers 
1977; Wade 1977 ; Altimore, 1982), and formulated recommendations on rDNA research most 
favorable to their interests (Krimsky, 1982).  Later, during open regulatory and Congressional 
debate, the emphasis on technical risks as initially framed by scientists dominated legislative and 
regulatory considerations.  A competing frame offered by other interests that emphasized the 
broader ethical and social implications of rDNA technology, including public participation in 
decision-making and the consideration of possible uses directed towards genetic engineering, 
was given considerably less attention and legitimacy (Krimsky, 1982;1991).   
Though in past surveys scientists have indicated that their chief reason for engaging the 
media is public education, other more self-serving motivations, including political interest or 
promotion of funding opportunities, are likely to be under reported (Peters, 1999). Indeed, 
scientists are often “sources with a mission” (Nelkin, 1995), especially when they perceive a 
threat to their interests.  In the rDNA debate, scientists perceived that what was at stake were the 
core values of science including freedom of inquiry, self-directed research, and peer review 
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(Krimsky, 1982).  There was strong sentiment among scientists that by being the first to call 
attention to possible risks of rDNA research, even as they framed the matter in a technical light, 
they had set in a motion a political process, and that scientists needed to deliver a strong political 
message in order to keep debate in-check (Turney, 1998). In the later half of the 1970s, as efforts 
towards local control and local regulation of research took place among approximately two 
dozen local or state governments nationally, with about half passing some form of regulation, 
scientists began “to close ranks,” with scientists who had previously raised concerns about 
research shifting position to form a scientific consensus, arguing that the risks to scientific 
autonomy now far outweighed any risks related to rDNA research (Krimsky, 1982).  Scientists 
sharpened their focus on technical risk, and delegitimated the public’s reaction as a case of mass 
hysteria or psychosis that was part of a growing “anti-science” movement (Turney, 1998).   
Scientists are not the only powerful interest to attempt to shape policy outcomes through 
influence of media coverage.  In an example of industry influence, during the early 1980s, media 
coverage was characterized by one-sided promotion of the biotechnology industry, with the press 
“held captive” by industry publicity.  Every new scientific finding was heralded by media reports 
as a major new cure or agricultural application.  The tone of coverage spurred continued 
investment from capitalists, and boosted public confidence in a new breed of “blue chip” stocks 
(Krimsky, 1991).  In the early 1990s, a decade after first industrialization efforts, only 15 biotech 
companies among several hundred had generated positive cash flow, forcing industry again to 
resort to circumspect press tactics.  In several lawsuits, industry interests were accused of using 
hyberbolic press releases to boost stock prices.  They were also accused of failing to disclose 
important negative information that might be harmful to share prices, yet important to investors 
(Cohen, 1992). 
Policymakers also work to frame biotechnology strategically, often to the benefit of 
industry interests.  The reason is that historically policymakers have considered biotechnology 
development critical to domestic economic growth, international competitiveness, and global 
security (Krimsky, 1991). Some of the most influential government attempts have taken the form 
of official government studies. In the early 1980s, investor optimism was boosted by a 1984 
Office of Technology Assessment (OTA) report that uncritically characterized biotechnology as 
a possible solution to many of the world’s problems including malnutrition, disease, energy 
availability, and pollution (OTA, 1984).   Later in the decade, the OTA released a 1987 national 
survey that was framed as evidence of heavy public enthusiasm and optimism regarding 
biotechnology, a tone that was reflected in press accounts related to the survey (Priest, 2001).  In 
reality, however, the OTA survey results revealed an American public that was mostly unaware 
of biotechnology.  Others have characterized the results as reflecting a public less enthusiastic 
than earlier surveys had indicated, with the public supporting more aggressive regulation (Priest, 
2001).   
Beyond official government reports and proceedings, other government actions can 
define issues related to biotechnology in potentially more subtle ways.  In 1987, when the U.S. 
Patent Office issued the first patent for a multi-cellular organism, among twenty-one pending 
applications they chose to inaugurate the “Cancer mouse,” a genetically-engineered lab rodent 
that could be used in specialized research on breast cancer.   The linkage of a divisive issue like 
the patenting of life with the symbol of progress towards a cure for cancer was not without its 
obvious positive media value, especially considering that the pending patent applications that 
were delayed until after the mouse announcement involved potentially more troubling images of 
deformed animal chimeras (Krimsky, 1991). 
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One historical policy analysis points to the cooperative efforts at issue definition between 
scientists, policymakers, and industry.  Plein (1995) asserts that during the 1970s, interests 
opposed to biotechnology were successful at conjuring images related to biotechnology of 
environmental risks, social uncertainty, and regulation.  However, beginning in the 1980s, 
industry, policymakers, and scientists working together were able to reframe biotechnology in a 
positive light.  These actors combined as a  “collective” voice of shared support, associating 
biotechnology with popular issues like local or state economic development, and American 
international competitiveness.  They were also successful at discrediting biotechnology 
opponents as extremists, and representing biotechnology opposition as led by just a few radical 
leaders, including legal “gadfly” and author Jeremy Rifkin. 
Although scientists, industry, and policymakers may hold the upper hand in shaping 
policy debate, other interests may attempt to use the media to increase their own legitimacy, 
visibility, or importance.  In 1971, when bioethicists Willard Gaylin and Daniel Callahan formed 
the Hastings Center as an institute to promote the study and public discussion of bioethics, both 
men decided that a focusing event was needed to draw public attention to the bioethics 
movement and to raise money for the Center.  Gaylin chose human cloning as the issue that 
would be most likely to catalyze public concern related to biological research, since it 
symbolized the lure of science, represented the possible negative outcomes of biological 
research, and fit well with a public aversion to cloning that stretched back to Mary Shelly’s 
Frankenstein.  Through ties at the paper, Gaylin lobbied the editorial staff of New York Times 
magazine to provide the forum for his discussion of human cloning.  His strategically framed 
article “The Frankenstein Myth Becomes Reality—We Have the Awful Knowledge to Make 
Exact Copies of Human Beings,” appeared in 1972, bringing national attention to the Hastings 
Center (Kolata, 1998).  
A shared culture between journalist and source. The media agenda-building and frame-
building process is not exclusively dominated, however, by competing interests and sources.  
Final coverage is attenuated in part by the routines of journalists, and the constraints of media 
organizations (Gans, 1979; Sigal 1973; Shoemaker and Reese, 1996).  The way journalists and 
interests view their job and their relationship, therefore, is the result of several levels of forces 
that are in constant dynamic interaction.  These interactions promote a shared culture between 
journalist and source that guides interaction, and sets an unofficial set of ground rules 
(Berkowitz, 1992).   
Related to science and biotechnology coverage, past research has highlighted the shared 
culture between the frequent contributor of science news, the science journalist, and their 
traditional sources, scientists (Nelkin, 1995).  Science journalists have historically viewed 
themselves as bridging the divide between the “professions” of journalist and scientist 
(Lewenstein, 1990).  As part of this shared culture between journalist and source, the complexity 
of science stories often leads science writers to favor information sources that are predominantly 
scientists, or intermediary public-information officers at universities, research institutes, or 
corporations, sometimes to the exclusion of other relevant actors. Science writers also tend to 
rely heavily on routine channels of information within the scientific community, including press 
releases, professional society meetings, press conferences, science journals, and interviews for 
story leads (Nelkin, 1995), often to the exclusion of other relevant, sometimes contradictory 
voices (Greenberg, 1997). Despite their claims to journalistic independence, science writers in 
their reporting tend to reflect the concerns of the scientific community, rather than those of the 
“public” they often claim to represent (Lewenstein, 1995). 
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In regards to the rDNA debates of the 1970s, science writers have been criticized for not 
featuring information and commentary from experts in relevant but non-science fields such as 
bioethicists studying the social impact and ethical implications of the technology, or economists 
studying industry development.  Science writers have also been criticized for failing to include 
input from members of the general public (Goodell, 1986).  
Among scientists, those that are university affiliated have been especially influential as 
sources for biotechnology news.  Besides filling a need for experts to gather, sort out, and 
explain technical information related to biotechnology, journalists prefer university scientists as 
sources because they are considered objective or neutral in their perspectives (Priest, 2001).  The 
unintended result is a likely source generated pro-biotechnology bias in media coverage since 
university scientists engaged in biotechnology research are often more positive in their outlook 
than other university scientists (Priest and Gillespie, 2000; Lyson, 2001; Priest, 2001).   
Although scientists are usually the dominant sources in coverage of science and 
biotechnology, often to the exclusion of other contradictory voices, crises or dramatic focusing 
events can sometimes create a shift in source influence (Berkowitz, 1992). For example, in 
reaction to the cloning events of 1997, journalistic orientations towards controversy, conflict, and 
drama served to emphasize the ethical implications of cloning technology, pitting the events and 
comments of scientists against the reaction of bioethicists, religious leaders, and other social or 
political actors.  The inclusion of these new sources in coverage meant that the ethics of human 
cloning came to dominate public discussion (Priest, 2001).   
Changing events can not only shift the balance of source influence, but they can also 
introduce new frames to a debate that may mobilize or allow access to interests previously not 
included in the media and policy agenda-building process (Gamson and Modigliani, 1989; 
Kingdon, 1984; Benford and Snow, 2000).  In 1999, after a letter to Nature reported evidence 
that Bt corn may be harmful to the Monarch butterfly, the media for the first time were able to 
report on a tangible possible threat related to agricultural biotechnology.  Opposition interests 
that had previously been marginalized in coverage emerged as narrators of the agricultural 
biotechnology controversy, able to provide the media with dramatic images of street theater and 
protest through mock-ups of “Franken-Tony the Tiger” and “Genetically-modified” corn flakes, 
or dancing human butterflies role-playing a Bt induced death beneath towering stalks of corn.  
Several interest groups, such as the Union of Concerned Scientists or the Environmental Defense 
Fund, that employed credentialed experts on agricultural biotechnology became important non-
university, non-government, and non-industry sources of technical information (Rissler, 2000).  
Other environmental groups that had been on the periphery of the agricultural biotechnology 
debate were now lured to the topic, and these groups subsequently devoted increased resources 
to the issue (Margulis, 2000), resulting in increased media and policy lobbying from interests 
opposed to the technology.  
Some issues related to biotechnology have failed to make it onto the elite media’s 
agenda, and instead have only received attention from regional or specialized news outlets.  The 
reason is that journalists often favor issues that they consider close to the interests of their 
readers or viewers (Shoemaker and Reese, 1996).  In an example of this “proximity” convention 
influencing media coverage of biotechnology, during the late 1980s and early 1990s debate over 
the marketing of Bovine Somatotropin (BST) produced milk, opposing interests launched 
intensive propaganda campaigns (Priest, 2001).  Yet the elite press, including the New York 
Times, paid little attention to the issue, likely considering BST of lesser interest to their broad 
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national readership.  Only at regional news outlets in agricultural states, including Wisconsin and 
Vermont, did BST-related issues receive prominent coverage (Priest, 2001). 
In other cases, however, regional media coverage can precede and spark widespread 
national media attention, which then impacts the policy agenda.  A clear example of this 
occurred with the controversy surrounding Dr. Richard Seed.  In December of 1997, at the end of 
a year of debate surrounding the possibility of human cloning, Seed announced at a scientific 
meeting in Chicago that he planned to raise money to open a human cloning clinic.  The first 
media account of Seed’s plans to clone humans appeared in the Washington Times on December 
11 (Price, 1997).  Seed’s claims did not receive national media attention, however, until January 
6 in an interview with Joe Palca (1998) on National Public Radio.  The radio report was followed 
by next day coverage appearing in the Washington Post (Weiss, 1998a).  Over the next two days, 
coverage of Seed’s claims appeared in print, television, and radio outlets across the country.  
Widely viewed as a reaction to the sudden and dramatic public attention given Seed’s claims, 
President Clinton in his end-of-the-week radio address urged Congress to pass previously stalled 
legislation to ban human cloning (Weiss, 1998b).  By mid-1998, both Republicans and 
Democrats had introduced legislation into the Senate (Dewar and Weiss, 1998). 
 
Previous Surveys of Press Coverage of Biotechnology 
As mentioned at the outset of this paper, few systematic, historical surveys of media 
coverage of biotechnology have taken place.  In several early qualitative studies, media coverage 
during the initial years of recombinant DNA development was characterized by a focus on risks 
and potential threats to public health (Goodell, 1980, 1986).  However, beginning with the 
Asilomar conference in 1976, scientists and their institutions began to strategically control media 
access to information.  As critics within the scientific community either reassessed their 
estimations of risk, or were silenced through peer-pressure, the character of coverage turned 
overwhelmingly positive, with few reported voices of dissent (Goodell, 1980; Altimore, 1982; 
Goodell, 1986).  In the late 1970s, when industry began to promote biotechnology development, 
media coverage shifted to emphasis on breakthroughs and economic benefits, again with few 
reservations reported.  This early coverage of biotechnology has been characterized as highly 
dependent on the sentiments of the scientists willing to engage the media, with “scientist-
proponents” overwhelming the “scientist-critics” (Goodell, 1986).   
 These qualitative assessments are in agreement with the results of an early quantitative 
study (Pfund and Hofstadter, 1981).  In 1976 and 1977, during the height of rDNA controversy, 
coverage in major newspapers, magazines, and medical or scientific journals regularly carried 
opinions from dissenting experts and laypersons, but by the end of 1977, reportage of dissident 
views had dramatically decreased.  By 1978, the importance of research benefits received the 
greatest attention in media coverage, with an emphasis on the potential for breakthrough 
discoveries, a heavy sourcing of industry-related actors, and a virtual absence of reporting on 
risks. 
In one of the few historical quantitative content analyses of media coverage of 
biotechnology, Washington Post coverage through the 1980s was dominated by frames of 
progress and economic prospect, with dominant themes including health-related applications, 
basic research, and industry development.  Coverage, however, began to turn slightly less 
positive in the years 1991 to 1996, with an increase in coverage of risks (Gaskell, Bauer, and 
Allum, 1999).   
 Biotech and the Elite Press, 1970 to 1999  - 10 - 
 
Other research has been specific to coverage of agricultural biotechnology. In several 
studies from the early 1990s, media coverage was characterized as failing to report on elements 
of political controversy.  Journalists depended heavily on information subsidies provided by 
industry and university public information officers.  University sources in particular were 
characterized as emphasizing the positive benefits of biotechnology, resulting in “boosterish” 
coverage that virtually ignored social, political, environmental, regulatory, or ethical concerns 
(Priest and Talbert; 1994; Beall and Hayes, 1996).  In a more recent time series analysis of 
agricultural biotechnology-related coverage appearing in the Wall Street Journal, USA Today, 
and Washington Post between 1990 and 1999, media attention among the elite papers gradually 
increased across the decade, with a jump in attention occurring as of 1997. Media coverage 
focused more on the associated risks of the technology than the benefits.  Also, early in the 
decade, the media, as a basis for comparison, tended to equate agricultural biotechnology with 
memorable catastrophic events, such as the nuclear accident at Chernobyl.  This trend of 
contextualizing agricultural biotechnology with references to recent historic catastrophes 
declined across the decade, only to begin an upward swing again in 1999 (Marks, 
Kalaitzandonakes, Allison, and Zakharova, 2000).   
 
Research Questions 
 The influential and interactive role of the media within the policy process, the many 
assumptions regarding the nature of press coverage of biotechnology, and the findings of 
previous research characterizing coverage of biotechnology, underscore the importance of a 
careful exploration and estimation of the amount and nature of media coverage of biotechnology 
over the past thirty years.  As mentioned at the outset of this paper, in the American context there 
has been little systematic comparison of biotechnology’s historical development with trends in 
media coverage.  And although previous qualitative assessments, case studies, and critical 
observations regarding biotechnology coverage offer valuable insights, in this paper we seek to 
compliment this previous research with a solid quantitative and historical description that sheds 
light on the underlying media-policy interaction.   
Due to the limited availability of previous quantitative research characterizing the nature 
of media coverage of biotechnology, and in light of somewhat conflicting findings, we decided 
to base the research in this paper on a set of relatively narrowly defined research questions 
instead of hypothesizing specific media trends: 
 
RQ1: What has been the level and nature of media attention to biotechnology?  
RQ2: What themes related to biotechnology have the media covered?  
RQ3: What have been the common media frames related to biotechnology? 
RQ4: What has been the tone of coverage related to biotechnology? 
RQ5: What sources or actors have been featured in biotechnology coverage? 
 
Method 
In exploring the above research questions, we are limited by the availability of historical 
data and by an economy of scale.  One method for investigating the evolving nature of media 
coverage in relation to the policy process and its competing interests involves the comparison of 
source information subsidies with media coverage outcomes, tallying the proportion of news 
releases or other information subsidy efforts that are either covered or discarded by the media 
(Berkowitz, 1992).    However, in the present study, spanning thirty years of media coverage, 
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most source materials are difficult to obtain or unavailable.  Instead, we chose to investigate final 
press coverage as the outcome of the underlying media agenda-building and frame-building 
process.  Our “visible source impact” approach (Berkowitz, 1992) focuses on the actors 
mentioned or featured in articles, the tone of coverage, and the dominant frames and themes 
exhibited.  In this approach, our findings can provide strong indicators of the most influential 
sources and interests that have shaped media coverage over the past thirty years.  The content 
analysis presented here involves analysis of various types of data collected between 1998 and 
2000, as part of an on-going coordination with a European Union (EU) study of biotechnology 
coverage appearing in several European countries (see Durant, Baur and Gaskell, 1998).  Due to 
differing key word and sampling strategies, however, our present study does not represent an 
exact replication of the EU research.   
We examined biotechnology-related coverage from the New York Times and Newsweek 
appearing between 1970 through the end of 1991.2  Coverage appearing in the opinion-leading 
publications like the New York Times or Newsweek are likely to represent the dominant tone of 
coverage in the United States. This choice to focus on the elite media compliments what other 
media analysts have observed: stories tend to spread vertically within the news hierarchy, with 
editors at regional news outlets often deferring to elite newspapers and newswires to set the 
national news agenda (Gitlin, 1980). (This trend, however, does not always hold, see for example 
the earlier discussion of BST coverage.) 
For this study we adapted measurement rules used by the EU-funded study of print 
coverage of biotechnology across 10 EU countries (Durant, Bauer, and Gaskell, 1998).  The rules 
allowed for measurement of both relatively manifest, objective article content as well as more 
latent and interpretive content such as themes, frames, and main references to actors.   
Measurement of themes provided an indicator of the type of biotechnology research, or 
the related economic, political, or social developments featured by journalists.  Coders chose up 
to three main themes per article.  Frames, as defined earlier, provided a second main measure of 
latent content.  Coders chose one main frame per article. Table 1 outlines a typology of frames 
applicable to biotechnology used in the current study.  This typology was adapted from the EU 
project (Durant, Baur and Gaskell, 1998), and originally developed in part by Gamson and 
Modgliani (1989).  Other latent measures included whether the article mentioned biotechnology-
related benefits and/or biotechnology-related risks, and whether an article reported on 
controversy.  We also included a measure of the main featured actors or sources in an article, 
with coders choosing up to two actors per article.3 
 
[Insert Table 1 Here] 
 
RESULTS 
Overall Press Attention, 1970 to 1999.  Figure 1 indicates that despite the rDNA debate 
of the 1970s, developments related to in vitro fertilization, and false claims or predictions related 
to human cloning, the New York Times and Newsweek paid limited attention to biotechnology.  
The major peaks in this decade’s limited coverage occurred in 1975, corresponding to the 
Asilomar conference and related events, and in 1977, when Congress held hearings and 
introduced legislation related to rDNA regulation. In 1980, only as industrial development of 
biotechnology began, did media attention to biotechnology increase, gradually rising across the 
1980s, peaking in 1988, then falling sharply in 1989 with the stock market crash and a temporary 
halt in industry growth.  In 1990, coverage began to increase again along with renewed industry 
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development.  Coverage peaked in 1992 when concern arose over possible over-valuation of 
biotech stocks, with most companies yet to turn a profit.  Media attention declined in 1993, but 
increased again in 1994 with market introduction of BST and the Flavr Savr tomato, and fast 
growth in biotech stocks.  Media coverage dipped during the mid-1990s, but peaked again in 
1997 with the announcement and debate surrounding cloning. Media coverage slightly decreased 
in 1998, then fell sharply again in 1999.   
 
[Insert Figure 1 About Here] 
 
It is important to keep in perspective the relative amount of media attention to 
biotechnology in comparison to the total universe of media coverage.  At its peak levels of 
coverage in 1992 and 1997, a biotechnology-related article appeared in only about one out of 
every three daily editions of the New York Times, and only about one out of every three weekly 
editions of Newsweek.  As recently as 1995 and 1996, twenty-five years after modern 
biotechnology’s invention, the New York Times featured the technology in only one out of every 
twelve daily editions.   
These estimations, however, are averages across a total year.  Media attention to an issue 
is rarely, if ever, equally distributed across time; instead media attention to biotechnology 
historically has been episodic, clustered around key focusing events or source actions,4 meaning 
that several articles could appear in one edition of the New York Times or several articles could 
appear across just a few days, or a period of a couple weeks.  In these clusters of media attention, 
for example following the 1997 Dolly announcement, biotechnology is likely to ride high on the 
overall media agenda in comparison to other newsworthy items.  
Evidence indicates that the “birth” of Dolly was considered by journalists to be a major 
news agenda item.  In reaction to the London-based Observer’s break of the Nature press 
embargo, the New York Times ran a late edition article on Dolly, with placement on the right-
hand side of page one, indicating the top story of the day (Kolata, 1998). The week following the 
Dolly announcement, both Newsweek and Time ran cover articles featuring the story. 6  At the 
end of the year, in the annual Associated Press poll of newspaper editors, Dolly was ranked as 
the fifth most important story of 1997 (Boorstein, 1997).  
If biotechnology can sometimes be prominent within a day’s, week’s, or month’s news, 
biotechnology-related issues could then go subsequently uncovered for an extended period of 
time until another focusing event or source-influence brings biotechnology back onto the media 
agenda.  When we took a closer look at the frequency of biotechnology-related coverage across 
month for the years 1997, 1998, and 1999, we found an unequal and episodic pattern of 
coverage.  In February and March of 1997, media attention to biotechnology peaked with the 
Dolly announcement and the ensuing public debate over cloning.  In June, media attention 
peaked again as the President and Congress announced plans for cloning legislation.  In January 
1998, with the claims of Dr. Richard Seed, media attention returned again to biotechnology, 
representing the greatest level of coverage for the year.  In 1999, media attention rose in June in 
response to the Nature Bt corn study, and in October and November in relation to the death of 
gene therapy patient Jesse Gelsinger, and the FDA public comment hearings on GM agriculture 
that sparked protests in major cities.  
In a final comparison that places media attention to biotechnology in context with media 
attention to other public affairs issues, or other issues related to science and technology, we ran 
article frequencies from the New York Times for various topics covered in 1997.  Table 2 
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indicates that, although biotechnology received greater or equal attention in the elite press than 
several events in 1997 that the media considered top stories, such as Mars Pathfinder, Heaven’s 
Gate, campaign finance reform, or the birth of septuplets; other technological or scientific issues 
received far greater attention including the Internet, nuclear energy, satellite communications, 
cellular phones, microchips or microprocessors, and climate change.  Other popular culture 
events such as the death of Princess Diana and Mother Teresa also received greater attention than 
biotechnology, as did the debate over assisted suicide, the Timothy McVeigh trial, and several 
major political issues.  These results indicate, that even at its peak levels of attention, 
biotechnology does not reside at the top of the media’s agenda in comparison to other major 
news items, even among other technology-related developments. 
 
[Insert Table 2 About Here] 
 
Coverage Content, 1970 to 1979. In Table 3, early applications of biotechnology featured 
in press coverage reflect the 1970s debate over rDNA technology and the related potential risk of 
microorganism release.  However, the potential of the new gene splicing techniques also brought 
attention to applications still in development including gene therapy, predictive medicine, and 
DNA research in general.  There was also early attention to gene mapping and the use of DNA in 
genetic fingerprinting related to crime. 
 
[Insert Table 3 About Here] 
As part of coverage during the 1970s, in vitro fertilization was also featured prominently.  
Coverage included a heavy focus on the themes of legal regulation in the second half of the 
decade as Congress, local communities, and regulators debated the safety and risks of rDNA 
research.  Voluntary regulations, ethical issues, and to a lesser extent economic prospects were 
also featured, but far less prominently.  General safety and risk was given prominent attention in 
the first half of the decade, but decreased in prominence in the later half of the 1970s.  Local 
community risk, laboratory-related risk, and environmental risk were given less coverage.  With 
the threat of environmental release, biodiversity was also given attention, but not prominently.  
Public opinion emerged as a theme in the second half of the decade as policy debate ensued, but 
was not given prominence.   
Table 4 indicates that the dominant frame across the decade was scientific progress, with 
only a few articles incorporating an ethical, public accountability, or economic prospect frame.  
Nearly a quarter of the articles appearing during the 1970s were assessed by coders as not 
featuring an applicable frame, a trend that decreased in years to come, possibly as journalists and 
competing interests began to develop routine framing devices for an emerging technology, with 
alternative considerations related to biotechnology never reaching the media agenda.   
 
[Insert Table 4 About Here] 
 
Table 5 indicates that mention of benefits of the technology far outweighed the mention 
of risks across the decade.  Reporting on controversy slightly increased in the second half of the 
decade as public debate over rDNA developed, but controversy was still only featured in less 
than half of biotechnology-related articles. 
 
[Insert Table 5 About Here] 
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In regards to the most prominent actors or sources featured in coverage during the 1970s, 
Table 6 shows that university scientists dominated coverage.  The DHHS and NIH, the principal 
Federal bodies to deal with the rDNA debate were also prominent.  With the debate over local 
regulation of rDNA, local and state governments were also featured.  Despite their involvement 
in the debate, our results indicate that other interests, including environmental and religious 
groups and bioethicists, for the most part, were excluded from coverage as featured actors. 
 
[Insert Table 6 About Here] 
 
Coverage Content, 1980 to 1989.  By the 1980s, with the rDNA debate resolved, 
coverage of microorganisms decreased, though the issue still remained in the press with events 
surrounding the regulation of the field release of genetically-modified organisms.  The most 
prominent themes in coverage, however, were general DNA research, issues related to human 
inheritance, and predictive medicine.  Despite the announcement in 1981 of what was thought to 
be the first successful cloning of mammals from undifferentiated embryo cells, animal cloning 
was not featured heavily among total coverage.  Also, although in vitro fertilization clinics 
opened across the country during the 1980s, coverage of this application increased only slightly.  
One likely reason was that in vitro clinics, in light of the increased targeting of abortion clinics 
by pro-life interests, deliberately chose to keep a low media profile in order to avoid drawing 
attention and controversy (Silver, 1998). 
In the early 1980s, the emergence of the biotechnology industry brought attention to 
pharmaceuticals and vaccines, the first biotechnology products to be publicly marketed.  Linked 
to biotechnology’s industrial development, economic prospects and agricultural research related 
to plant breeding were also featured.  Economic development brought attention to patenting and 
property rights.  Even though the new federal regulatory framework established in 1986 was a 
major development in biotechnology’s short history, legal regulation received only marginal 
coverage as a theme during the 1980s, a dramatic departure from coverage of the late 1970s. 
Other related themes to the regulatory restructuring including general biotech policy and labeling 
also received little attention. Attention to general safety and risk increased during the 1980s, but 
coverage of specific risks to the environment or to local communities went virtually uncovered 
as a major theme.  The same held true for coverage of public opinion or general public fear of 
biotechnology. 
During the 1980s, scientific progress increased in prominence as the dominant frame 
related to biotechnology, and economic prospect emerged as a secondary frame.  Other 
alternative ways of framing biotechnology were not found in media coverage.  The percentage of 
articles reporting on controversy dropped dramatically during the 1980s, as the issues associated 
with biotechnology moved from debate over rDNA risks to focus on industrial and economic 
development.  With a decrease in political debate and reported controversy, fewer articles 
included direct mention of either benefits or risks, although positive evaluations of the 
technology still heavily outnumbered negative evaluations.   
During the 1980s, university scientists still dominated as featured actors in coverage, as 
research and development was closely linked to the university-government-industry complex.  
However, with the economic development related to biotechnology that began in the 1980s, 
industry members, and to a lesser extent industry scientists, emerged as a second dominant actor 
next to university scientists.  The DHHS and NIH remained prominent, and a few stories began 
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to cover other regulatory agencies including the EPA and USDA, as regulatory responsibility 
was debated and eventually reformulated.  With increased industrial development, the U.S. 
patenting office also emerged as a featured actor, as did the Federal judiciary, with a number of 
court battles either over patenting and property rights, or several legal challenges to 
biotechnology regulation.  Similar to trends from the 1970s, other interests including 
environmental, consumer, or religious groups, as well as bioethicists were not prominent actors 
in coverage 
Coverage Content, 1990 to 1999.  The first half of the 1990s was relatively similar to the 
1980s in coverage of themes, with a dominant emphasis on DNA research in general, 
pharmaceuticals and vaccines, human inheritance, and predictive medicine.  Coverage of gene 
therapy, with the first human trials approved in 1991, increased during the early 1990s, but did 
not comprise a significant proportion of coverage. Related to gene therapy trials and the growing 
popularity of in vitro fertilization there was the reemergence of media attention to voluntary 
regulations.  There was also a sharp increase in coverage of ethical issues.  Mentioned in nearly a 
third of all articles, the early 1990s mark the first time consideration of ethics is given prominent 
attention by the media.  Despite major product development related to agricultural 
biotechnology, GMO release and plant breeding are not given prominent coverage. 
 With the cloning announcements and resulting political debate of 1997 and 1998, media 
coverage of the later half of the 1990s was dominated by media attention to human and animal 
cloning.  Also, with news of the first results of gene therapy trials that arrived mid-decade, and 
the 1999 death of Jesse Gelsinger, there was a significant increase in media attention to gene 
therapy.  With the events of 1999, media attention to GMO release also increased, though in 
comparison to other issues, it was not a prominent theme for the five-year period.  Attention to 
plant breeding accounted for only a small proportion of coverage, as did agricultural 
biotechnology related themes of food safety and biodiversity.   
With cloning capturing much of the media’s attention to biotechnology in 1997 and 1998, 
media coverage of DNA research in general, human inheritance, and predictive medicine 
decreased.   A focus on ethical issues appeared in about a third of all articles in the later 1990s.  
There was also heightened attention to legal regulation, and for the first time in biotechnology’s 
history there was significant coverage of public opinion. 
 In the early 1990s, the media’s use of frames changed little from the previous decade, 
with an overwhelming focus on scientific progress and economic prospect.  In the second half of 
the 1990s, however, cloning and later events related to agricultural biotechnology likely brought 
for the first time a substantial proportion of articles featuring an ethical frame, with this 
organizing device eclipsing the proportion of articles centered on economic prospect.  This five-
year period of coverage represents the greatest diversity of biotechnology frames across the 
thirty year period of our analysis. 
Reporting of conflict jumped dramatically during the last half of the 1990s, with close to 
seventy percent of articles featuring controversy.  There was also much heavier mention of risks 
in media coverage.  Though reporting on negative aspects of biotechnology appears to have 
increased during the events the late 1990s, the media also included greater coverage of 
biotechnology’s benefits.   
 Trends regarding featured actors during the first part of the 1990s followed closely those 
in the 1970s and 1980s, with university scientists and industry members continuing to dominate 
coverage. The events of the last half of the 1990s, however, brought a dramatic shift in featured 
actors, with for the first time an emphasis on media coverage of the public as a major actor in the 
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biotechnology debate.  Media coverage also featured a greater focus on the Presidency, ethics 
committees, and a slightly decreased prominence for university scientists and industry members.  
The personal celebrity gained by Roslin Institute scientist Ian Wilmut with the Dolly 
announcement increased considerably the measure of attention to scientists from private 
institutes.  Religious interests also increased in prominence, though still only appearing as major 
actors in a few articles. Other interests, however, despite their increased efforts during the late 
1990s, including environmental, consumer, and agricultural interests, remained on the periphery 




Our content analysis identifies some important trends in media coverage of 
biotechnology over the first three decades of its research, development, and application.  Before 
we elaborate on the implications of our findings, however, it is necessary to look more closely at 
some of the technical aspects of our study. 
 
Some data related considerations. 
This study was limited to a content analysis of one national elite newspaper and one 
national elite news magazine.  Although, as mentioned earlier, there are valid reasons for 
limiting this specific study to just those two publications, we are constrained to some degree in 
our ability to generalize to all American print outlets, or to non-print media sources.  We are also 
constrained in our ability to reach final conclusions regarding the relationship between media 
coverage and competing interests involved in biotechnology-related policy development. Content 
analysis only allows for non-obtrusive observation of the final product of the media agenda-
building and frame-building process, and even though several valid and reliable interpretations 
are possible from this type of analysis, there remains some degree of uncertainty regarding the 
actual inputs to the process or the specifics of the process itself.  Other studies should 
complement our “visible source impact” approach with a tallying of source-media coverage 
success rates, or with qualitative observations and interviews related to source-journalist 
interactions.   
Our study also canvasses three decades of coverage related to multiple facets and issues 
within and related to biotechnology development.  In adopting this approach, we gain a broad 
picture of overall trends related to biotechnology coverage, but we also lose some precision in 
measurement, as each facet of biotechnology, from plant biotechnology to human cloning, 
involves certain unique interests, themes, actors, and political interactions.  In this direction, we 
recommend that future studies adopt our historical approach, but applied to just one dimension of 
biotechnology, involving either content analysis or more qualitative case studies. 
 
Outlook. 
 Media attention to biotechnology. Our analysis of trends in media attention to 
biotechnology makes clear that biotechnology has steadily entered the public and policy sphere 
over the last three decades, with coverage gradually rising across each decade, following for the 
most part the growth in the biotechnology industry, and the general level of technological and 
scientific development as indicated by increases in overall research and development, and market 
introduction of biotech products.  Biotechnology coverage has been heavily event-centered or 
episodic within years, peaking or plummeting across week or month in correspondence to the 
 Biotech and the Elite Press, 1970 to 1999  - 17 - 
 
latest major article appearing in Science or Nature, the announcements of politicians or 
regulatory bodies, a major announcement at a scientific meeting, or the occasional high-profile 
incidents like the claims of scientist Richard Seed, the protests at the 1999 WTO meetings, or the 
death of gene therapy patient Jesse Gelsinger.  Media coverage may ride high on the media 
agenda for a specific week or month surrounding major focusing events, but biotechnology 
across any one year still rests rather modestly on the media agenda compared to other major 
political issues, or even other science and technology-related developments. 
Character of coverage.  In regard to tone, for the most part, our findings agree with 
previous studies: biotechnology coverage has been typified by an overwhelming absence of 
reporting on controversy, with coverage of benefits greater than coverage of potential risks.  
There are two exceptions to this generalization.  In the late 1970s, there was elevated levels of 
reporting of controversy and risks linked to the rDNA debate. (Though risks still did not 
outnumber mention of benefits.)  This aspect of coverage was even more prominent in the later 
half of the 1990s as controversy emerged surrounding cloning, and to a lesser extent gene 
therapy and agricultural biotechnology.   
It appears that during these periods of heightened political controversy, media negativity 
increases, but not without also a proportional increase in positive coverage from the media.  
Here, two influences are likely at work.  First, in times of political controversy surrounding 
biotechnology, interests on both sides of the debate increase their lobbying of the media, creating 
a greater number of competing claims to feature in coverage.  Second, the objectivity norm of 
journalism is likely to create a polarizing effect, with every negative consideration featured in an 
article counterbalanced by a positive consideration related to biotechnology.  In this regard, our 
quantitative findings agree with previous qualitative assessment of the late 1990s coverage of 
cloning (Priest, 2001). 
Source influence.  In assessing overall source influence, scientists, industry, and 
government actors have dominated coverage.  This conclusion of a “mobilization of bias” and 
hegemonic influence of media coverage is supported by the results indicating the main actors 
that have been most frequently featured in coverage across time, as well as the consistent pro-
biotechnology tone in coverage.  It is also supported by the dominance of framing devices that 
accent elements of scientific progress and economic development, as well as the heavy 
prominence of themes that highlight the development of pharmaceuticals and vaccines, or 
emphasize patenting or property rights.  Scientists and industry also appear influential in what 
issues are not covered by the media, including ethics, legal regulation, public opinion, and other 
competing interests including environmentalists, religious groups, bioethicists, consumer groups, 
and the public in general. 
Several instances of what appear to be “nondecision making” episodes, where lack of 
media attention may have allowed a few interests to control policy, also support the likelihood of 
strong scientist, government, and industry source influence.  In one example, during the late 
1980s when the Federal government substantially reformulated biotechnology regulation in a 
fashion that promoted industry development, our media findings reflect little attention to themes 
of legal regulation, and show little impact by non-industry, non-government, or non-scientist 
sources.  In an example involving the nondecision-making influence of government-related 
sources, the military is rarely if ever mentioned in connection to biotechnology across the thirty 
years of our analysis.  Yet, second only to the NIH, the U.S. Defense Department has historically 
been the major federal sponsor of biotechnology research and development (Krimsky, 1991), 
suggesting that much of biotechnology research related to weapons or military applications has 
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remained outside the media’s agenda.  These “uncontroversies” and “nondecisions” are 
facilitated in part by a likely spiral of silence process, where one-sided media coverage cultivates 
the perception that consensus elite or general public opinion regarding biotechnology agrees with 
industry, scientists, and government positions.  This perception, whether accurate or inaccurate, 
undermines the ability of dissenting interests to mobilize public opposition, or even call attention 
to important policy decisions. 
The pro-biotechnology tone of media coverage, and the dominance of science, industry, 
or government sources are also attributable to journalistic preferences, as the media have relied 
heavily on these sources for technical information and routine channel news.  The fact that the 
source-journalist interaction has benefited pro-biotechnology sources at the expense of dissenting 
interests is promoted by a favorable run of history in the United States.  Unlike other major 
industrial developments of the past half-century--including chemical, petroleum, and nuclear 
energy technologies—there have been no major catastrophes related to biotechnology. An 
accident on the scale of Bhopal, Love Canal, Chernobyl, or Three Mile Island related to 
biotechnology would likely shift the rules of engagement between journalists and sources, 
lending greater legitimacy to certain interests that historically have been locked outside what 
Schattsneider (1960) characterizes as a restricted policy pressure system.   
In the American context, government agencies and scientists are widely considered 
credible and necessary authorities in matters of scientific and environmental uncertainty.  In a 
world of increasing technological complexity that brings new and unknown risks, the public is 
heavily dependent on these experts and their institutions for reassurances and reliable 
information (Giddens, 1990; Beck, 1992). However, if events undermine the legitimacy of these 
sources, as was the case in the United Kingdom after the discovery and publicity surrounding 
Mad Cow disease, or was the case in Europe after inaccurate reassurances related to Chernobyl 
fall out, other social actors including environmental, religious, and consumer interests are likely 
to take on the role of expert in the media (Jasanoff, 1997).   
The events surrounding cloning in 1997 and 1998, and to a lesser degree the 
circumstances surrounding GM agriculture and gene therapy in 1999, offer some, but still 
limited, elements of biotechnology-related “crisis.”  For the most part, the scientific 
establishment, science journalists, bioethicists, and religious leaders were caught off guard by the 
Dolly announcement of 1997 (Kolata, 1998; Silver, 1998).  More importantly, the sudden 
possibility of human cloning expanded the political arena surrounding biotechnology policy 
debate to include other interests than just scientists, industry, or government, legitimating the 
concerns of bioethicists, religious leaders, and the general public.  With lesser impact, debate 
surrounding agricultural biotechnology and gene therapy likely served to also broaden the 
political arena. This re-framing of biotechnology that suddenly helped mobilize and include a 
greater diversity of actors and perspectives in media coverage is supported by our findings that 
mark the latter half of the 1990s as the first period to include wider discussion of ethics, public 
accountability, and mention of the public, along with heightened reporting of controversy.  
Future and on-going research should examine which features unique to press coverage in the last 
part of the 1990s have carried into biotechnology’s new millennium. 
 
 




1. Kindgon (1984) defines the policy agenda as the list of subjects or problems to which 
governmental officials, and people outside of government closely associated with those officials, 
are paying some serious attention to at any given time (Kingdon, 1984; Linsky, 1986). 
 
2. In this analysis, we combine data first gathered and coded in 1998, with data gathered and 
coded in 2000.  In the first study conducted in 1998, the full text of articles was obtained for the 
twenty-five year period starting in 1970 and ending in 1994.  In the second study, full text 
articles were gathered for the five-year period 1995 to 1999.  In both instances, a population of 
articles from the two publications was constructed using a Lexis-Nexis database search of key 
words related to biotechnology.  All articles from the two publications that contained in the 
headline or the lead paragraph any of the key words or parts of key words “biotech*,” “clone,” 
“cloning,” “genetic engineer*,” “gene manipulat*,” “gene technolog*,” “gene therap*,” or 
“recombinant DNA” were selected.  For purposes of this study, we did not include the key word 
“genome.” The Human Genome project, though related to the larger development of 
biotechnology historically, has a unique set of events and features that place it beyond the proper 
scope of this study.  
The full text of articles available in Lexis-Nexis for the New York Times is only available 
back to 1981, and for Newsweek only available back to 1975. For both publications, library 
content indices were consulted for relevant articles not included in the Lexis database, and 
photocopies of articles were retrieved from either microfiche or microfilm. For articles retrieved 
through Lexis-Nexis, once a population was determined, non-biotechnology articles were 
excluded that contained similar words but were used in contexts unrelated to biotechnology (e.g., 
articles covering computer clones). The search for the years 1970 to 1994 resulted in a 
population of 948 articles.  The search for the years 1995 to 1999 resulted in a final population of 
356 articles across the two publications for the five years of our study.  Due to the constraints on 
index availability for articles appearing during the 1970s, it is likely that our population slightly 
underestimates rather than overestimates the population of relevant biotechnology-related 
articles for both publications during this decade. 
The full population of articles retrieved appearing between 1970 to 1995 were used in 
coding.  For the 1995 to 1999 population, a 33.3% probability sample of the population of 
articles from the New York Times was selected and combined with the complete population of 
articles from Newsweek, resulting in a representative coding sample of 137 articles.  Sampling 
procedures for 1995 to 1999 were used due to the inclusion of a greater number of publications 
in the originally defined population of news coverage, though as outlined earlier, for comparative 
purposes, only findings related to the New York Times and Newsweek are included in this paper.  
Regardless, employing probability techniques in our sampling of New York Times coverage 
leaves us confident that our content data is representative of total New York Times coverage 
appearing across the five years. 
 
3. Two sets of coders were used.  One set of two coders (team A) for the 1970 to 1994 
population of articles, and a different set of two coders (team B) for the 1995 to 1999 sample.  
For coding team A, inter-coder reliability across the variables used in this study was for themes 
(r =.55), frames (r =.52), risk (r =.81), benefit (r =.78), controversy (r =.58), and actor (r =.43).  
For coding team B, inter-coder reliability across the variables used in this study was for themes 
(r =.44), frames (r =.47), risk (r =.73), benefit (r =.71), controversy (r =.50), and actor (r =.48).  
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These lower than ideal reliability results are due to 1) a correlation comparison using 
dichotomous variables, and 2) the strong tension that occurs in quantitative content analysis 
between highly reliable measurement of often less interesting manifest data versus the less 
reliable, but often more valid measurement of more interesting latent variables.  Moreover, the 
rating results reported here are equivalent to the results achieved by other researchers applying 
similar coding rules to media coverage across countries in Europe (Durant, Baur and Gaskell, 
1998).   
 
4. In some cases, media attention may be almost totally journalist driven, with editorial decisions 
made to give attention to an issue without an apparent focusing event or source influence.  These 
types of articles are difficult to identify without confirmation from journalists themselves, who 
even then may be reluctant to reveal their motivations for running a story.   
 
5. In an example of the organizational restraints that might often influence media agenda-
building, James Fallows, editor of U.S. News and World Report at the time, decided to run a 
previously scheduled cover article on the nation’s top graduate schools instead of coverage of 
cloning.  Later, in regret, Fallows would comment that Dolly was the most important story of the 
last two or three decades (Kolata, 1998). 
 
6. Lexis-Nexis search terms for each of the issues displayed in table 2 include “internet,” 
“federal reserve,” “nuclear energy or nuclear power or atomic energy or atomic power and/not 
weapon or missile or bomb,” “assisted suicide,” “hurricanes or monsoons,” “global warming or 
climate change or greenhouse gas or greenhouse effect,” “whitewater and Clinton,” “gun 
control,” “cellular phones or mobile phones,” “Timothy McVeigh,” “Mir Space Station,” 
“microchips or microprocessors,” “welfare reform,” “satellite and telecommunications,” 
“tobacco lawsuits,” “Princess Diana,” “Space Shuttle,” “Mother Teresa,” “tax reform,” 
“earthquake,” “Beatles or Rolling Stones,” “Heaven’s Gate,” “campaign finance reform,” 
“biotech* or clone or cloning or genetic engineer* or gene manipulat* or gene technolog* or 
gene therap* or recombinant DNA,” “EPA and air pollution and regulation,” “solar energy or 
solar power,” “Mars Pathfinder,” “high definition television or HDTV,” “alternative medicine or 
complimentary medicine,” “breast implants,” “mammograms,” “Hubble telescope,” 
“Septuplets,” “electric cars or electric powered cars,” “Alien abduction or UFOs or Roswell New 
Mexico,” “endangered species,” and “human genome.” 
  





Altimore, M. 1982.  The social construction of scientific controversy.  Science, Technology, and  
Human Values, 7: 24-31. 
 
Bachrach, P. and M. Baratz. 1970.  Power and poverty.  New York: Oxford. 
 
Beall, G.A. and J.H. Hayes. 1996.  Agricultural biotechnology: What is news and who are the 
sources.  Paper presented at the Public Communication of Science and Technology 
Conference—4, Melbourne, Australia, February. 
 
Beck, U. 1992. Risk Society: Towards a new modernity.  London, UK: Sage Publications. 
 
Benford, R. and R. Snow. 2000. Framing processes and social movements: An overview and  
assessment. Annual Review of Sociology, 26: 611-639. 
 
Berkowitz, D. 1992.  Who sets the media agenda?  The ability of policymakers to determine  
news decisions. In Public opinion, the press, and public policy, edited by J.D. Kennamer, 81-
102. Westport, CT, Praeger. 
 
Boorstein, M. 1997.  Diana, Mother Teresa, and McVeigh conviction top stories of  
1997.  Associated Press, 26 December, AM cycle. 
 
Cobb, R.W. and C. Elder. 1971.  The politics of agenda-building: An alternative perspective for  
modern democratic theory.  Journal of Politics, 33, 892-915. 
 
Cohen, L.P. 1992.  Some biotech firms excel at state-of-the-art hype.  Wall Street  
Journal, 13 March, C1. 
 
Cozzens, S.E. and E.J. Woodhouse. 1995.  Science, government, and the politics of knowledge.    
In Handbook of science and technology studies, edited by S. Jasanoff, G.E. Markle, J.C. 
Peterson, and T. Pinch, 533-553.  Thousand Oaks: Sage. 
 
Danielan, L. 1992.  Interest groups in the news. In Public opinion, the press, and public policy, 
edited by J.D. Kennamer, 63-79.  Westport, CT: Praeger. 
 
Dewar, H. and R. Weiss. 1998.  Senate blocks GOP drive to quickly ban human cloning. 
Washington Post, 12 February, A12. 
 
Durant, J., M. Bauer, and G. Gaskell, eds. 1998.  Biotechnology in the public sphere: A  




Hallin, D. 1987.  Hegemony: The American news media from Vietnam to El Salvador: A study  
 Biotech and the Elite Press, 1970 to 1999  - 22 - 
 
in ideological changes and its limits.  In Political communication research: Approaches, studies, 
assessments, edited by D. Paletz, 3-25.  Norwood, NJ: Ablex. 
 
Gamson, W. and A. Modigliani. 1989. Media discourse and public opinion on nuclear power: A  
constructionist approach. American Journal of Sociology 95:1-37. 
 
Gandy, O.H. Jr. 1982.  Beyond agenda-setting: Information subsidies and public policy.  
Norwood, NJ: Ablex. 
 
Gans, H.G. 1979.  Deciding what’s news: A study of CBC evening news, NBC nightly news,  
Newsweek, and Time.  New York: Vintage Books 
 
Gaskell, G., M. Bauer, J. Durant, T. Allum. 1999.  Worlds apart?  The reception of genetically 
modified foods in Europe and the U.S.  Science, 285:384-387. 
Gaskell, G., M. Bauer, and J. Durant. 1998.  The representation of biotechnology: policy, media, 
and public perception.  In Biotechnology in the Public Sphere: A European Source Book, edited 
by J. Durant, M. Bauer, and G. Gaskell, 3-14.  London, UK: Science Museum. 
 
Gaylin, W. 1972.  The Frankenstein myth becomes reality. New York Times Magazine, 5 March. 
 
Giddens, A. 1990.  The consequences of modernity.  Stanford, CA: Stanford University Press. 
 
Gitlin, T. 1980. The whole world is watching: Mass media in the making and unmaking of the 
new left. Berkeley: University of California Press.  
 
Goodell, R. 1977.  Visible scientists. Boston: Little, Brown. 
 
Goodell, R. 1980.  The gene craze.  Columbia Journalism Review 4:41-45. 
 
Goodell, R. 1986.  How to kill a controversy: The case of recombinant DNA.  In Scientists and 
journalists: Reporting science as news, edited by S. Friedman, S. Dunwoody, and C. Rogers, 
170-182. Washington, D.C.: Washington, D.C. 
 
Greenberg, J. 1997. Using sources.  In A Field Guide to Science Writers, edited by D. Blum and 
M. Knudson, 94-102.  New York: Oxford University Press. 
 
Jasanoff, S.  1997.  Civilization and madness: The great BSE scare of 1996.  Public 
Understanding of Science 6:221-232. 
 
Kingdon, J.W. 1984.  Agendas, alternatives, and public policies.  New York: Harper Collins. 
 
Kolata, G. 1998.  Clone: The road to dolly and the path ahead. New York: William Morrow and 
Company. 
 
 Biotech and the Elite Press, 1970 to 1999  - 23 - 
 
Krimsky, S. 1982.  Genetic alchemy: The social history of recombinant DNA controversy. 
Cambridge: MIT Press. 
 
Krimsky, S. 1991. Biotechnics and society:  The rise of industrial genetics. Westport, CT: 
Praeger. 
 
Lewenstein, B. 1990. Science Writing: The Development of a New Profession. Unpublished 
manuscript. 
 
Lewenstein, B. 1995.  Science and the media.  In Handbook of science and technology studies, 
edited by S. Jasanoff, G.E. Markle, J.C. Peterson, and T. Pinch, 343-360.  Thousand Oaks: Sage. 
 
Licther, R. and S. Rothman.1999.  Environmental cancer—A political disease?  New Haven: 
Yale University Press. 
 
Linsky, M. 1986.  Impact: How the press affects federal policymaking. New York: W.W. 
Norton. 
 
Lyson, T.A. 2001. How do agricultural scientists view advanced biotechnologies? Chemical 
Innovation 31:50-53. 
 
Margulis, C. 2000.  Campaign director, genetic engineering, Greenpeace, U.S.A.   
Personal interview with author, Washington, D.C, January. 
 
Marks, L., N. Kalaitzandonakes, K. Allison, and L. Zakharova, 2000.  Time series  
analysis of risk frames in media communication of agrobiotechnology.  Paper presented at the 4th 
International Conference on “The Economics of Agricultural Biotechnology,” Ravello, Italy, 
August. 
 
Miller, M.M. and Reichert, B.P. 2000.  Interest group strategies and journalist norms: News 
media framing of environmental risks, 45-54.  In Environmental risks and the media, edited by 
S. Allan, B. Adam, and C. Carter. London: Routledge. 
 
Nelkin, D. 1995. Selling science: How the press covers science and technology. New York: 
W.H. Freeman.   
 
Noelle-Neumann, E. 1984.  Spiral of silence: Our social skin.  Chicago: University of Chicago 
Press. 
 
Office of Technology Assessment. 1984.  Commercial biotechnology. Washington, D.C.:  
U.S. Government Printing Office. 
 
Office of Technology Assessment. 1987.  New developments in biotechnology. Public 
perceptions of biotechnology.  Washington, D.C.: U.S. Government Printing Office. 
 
 Biotech and the Elite Press, 1970 to 1999  - 24 - 
 
Palca, J. 1998.  Interview with Richard Seed. "All Things Considered,” National Public Radio, 6 
January. 
 
Peters, H.P. 1999.  The interaction of journalists and scientific experts: Cooperation and  
conflict between two professional cultures.  In Communication science: Contexts and channels, 
reader 2, edited by E. Scanlon, E. Whitelegg, and S. Yates, 252-269. London: Routledge. 
 
Pfund, N. and Hofstadter, L. 1981. Biomedical innovation and the press. Journal of 
Communication 31:138-154. 
 
Plein, L.C. 1995. Popularizing biotechnology: The influence of issue definition.  Science, 
Technology, and Human Values, 16:474-490 
 
Price, J.H. 1997.  Cloning touted as infertility solution; Biologist’s proposal draws threat of ban.  
Washington Times, 11 December, A9. 
 
Priest, S.H. 2001.  A grain of truth: The media, the public, and biotechnology. New York: 
Rowman and Littlefield. 
 
Priest, S.H and A. Gillespie. 2000. Seeds of discontent: Expert opinion, mass media, and the  
public image of agricultural biotechnology. Science and Engineering Ethics 6:529-539. 
 
Priest, S.H. and J. Talbert. 1994.  Mass media and the ultimate technological fix: Newspaper  
coverage of biotechnology.  Southwestern Mass Communication Journal 10:76-85. 
 
Rissler, J. 2000.  Staff scientist, Union of Concerned Scientists.  Personal interview  
with author, Washington, D.C, January. 
 
Rogers, M. 1977. Biohazard: The struggle to control recombinant DNA experiments, the most  
promising (and most threatening) scientific research ever undertaken.  New York: Knopf. 
 
Schattsneider, E. E. 1960.  The semi-sovereign people.  New York: Holt. 
 
Scheufele, D.A. 1999.  Framing as a theory of media effects. Journal of Communication 29:103-
123. 
 
Scheufele, D.A. and P. Moy. 2000.  Twenty-five years of the spiral of silence: A conceptual 
review and empirical outlook.  International Journal of Public Opinion Research 12:3-28. 
 
Schön, D.A. and M. Rein. 1994.  Frame reflection: Toward the resolution of intractable policy 
controversies. New York: Basic Books.  
 
Shoemaker, P.J. and S.D. Reese. 1996.  Mediating the message: Theories of Influences on mass 
media content. 2nd edition. New York: Longman. 
 
 Biotech and the Elite Press, 1970 to 1999  - 25 - 
 
Sigal, L. 1973. Reporters and officials: The organization and politics of newsmaking. Lexington, 
MA: Heath. 
 
Silver, L.M. 1998.  Remaking eden: How genetic engineering and cloning will transform the  
American family.  New York: Avon. 
 
Soloski, J. 1989. Sources and channels of local news.  Journalism Quarterly 66:864-870. 
 
Tuchman, G.1978. Making news: A study in the construction of reality. New York: Free Press. 
 
Turney, J.1998.  Frankenstein’s footsteps: Science, genetics, and popular culture.  New Haven, 
CT: Yale University Press. 
 
Wade, N. 1977. The ultimate experiment: Man-made evolution.  New York: Walker. 
 
Weiss, R. 1998a.  Scientist plans to clone humans; Anticipating ban, researcher says he  
has assembled doctors, volunteers.  Washington Post, 7 January, A3 
 
Weiss, R. 1998b.  Clinton presses ban on human cloning; Statement a response to fears   
of attempts unless congress acts.  Washington Post, 11 January, A6. 
 




Matthew C. Nisbet is a PhD candidate in the Department of Communication at Cornell 
University where Bruce V. Lewenstein is an Associate Professor.  Address correspondence to the 
first author.  The Media and Society Research Group (MSRG) is an interdisciplinary 
collaboration between faculty and graduate students at Cornell University.  Funding for this 
research was provided by a USDA Hatch grant (NYS 131-7415), and by a graduate summer 
fellowship from the Cornell University Genomics Initiative: Ethical, Legal, and Social 
Implications (ELSI).  Shobita Parthasarathy, Tracy Allaman, Lisa Pinsker, and Jon Preall served 
as coders for the content analysis.  The authors would like to thank James Shanahan and Dietram 
Scheufele of Cornell University, Susanna Hornig Priest of Texas A&M University, and three 
anonymous reviewers for comments on previous drafts of this research. 
 
 
 Biotech and the Elite Press, 1970 to 1999  - 27 - 
 
TABLE 1 
A Framing Typology for Biotechnology 
 
NOTE:  Framing typology is adapted from Durant, Baur and Gaskell (1998), and originally developed in part by 
Gamson and Modgliani (1989).    
“Progress”:  celebration of new development, breakthrough; direction of history; conflict between 
progressive/conservative-reactionary. 
 
“Economic prospect”: economic potential; prospects for investment and profits; RandD arguments. 
“Ethical”: call for ethical principles; thresholds; boundaries; distinctions between acceptable/unacceptable 
risks in discussions on known risks; dilemmas.  Professional ethics. 
 
“Pandora’s Box”: call for restraint in the face of the unknown risk; the opening of flood gates warning; 
unknown risks as anticipated threats; catastrophe warning. 
 
“Runaway”: fatalism after the innovation; having adopted the new technology/products a price may well 
have to be paid in the future; no control any more after the event. 
 
“Nature/Nurture”: environmental vs. genetic determination; inheritance issues. 
 
 
“Public accountability”: call for public control, participation, public involvement; regulatory mechanisms; 
private versus public interests. 
 
“Globalization”: call for global perspective; national competitiveness within a global economy; opposite: 
splendid isolation. 
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TABLE 2 
Topical Media Attention, 1997 
Internet, 1000+                                             Beatles or Rolling Stones, 139 
Federal Reserve, 892                   Heaven’s Gate, 127 
Nuclear energy, 458                       Campaign finance reform, 124 
Assisted suicide, 446                       Biotechnology, 120 
Hurricanes or monsoons, 427           EPA air pollution regulations, 111 
Climate change, 252 Titanic, 110 
Whitewater, 241 Solar energy or power, 86 
Gun control, 234 Steven Spielberg, 82 
Cellular or mobile phones, 213 Mars Pathfinder, 75 
Timothy McVeigh trial, 203 HDTV, 67 
Mir Space Station, 201 Alternative medicine, 66 
Microchips or microprocessors, 195 Breast implants, 58 
Welfare reform, 183 Mammograms, 57 
Satellite telecommunications, 182 Hubble Telescope, 54 
Tobacco lawsuits, 181 Septuplets, 45 
Princess Diana, 174 Electric powered cars, 39 
Space Shuttle, 173 Alien abduction, UFOs, Roswell, NM, 30 
Mother Teresa, 151 Endangered species, 24 
Tax reform, 143 Human Genome Project, 16 
Earthquakes, 139  
 
Source: Lexis-Nexis Universe index of New York Times for 1997 
 
NOTE: The issues chosen for comparison with biotechnology are derived in part from the top ten stories of 1997 as 
indicated by the end-of-the-year Associated Press poll of newspaper editors including 1) the death of Princess 
Diana; 2) the Timothy McVeigh trial; 3) the death of Mother Teresa; 4) the economic boom (represented here by 
articles related to a major economic actor, the Federal Reserve, and the Internet); 5) the announcement of Dolly and 
resulting cloning debate; 6) the birth of septuplets; 7) the tobacco lawsuit settlement; 8) Mars Pathfinder; 9) 
campaign finance reform-related scandals including Asian donors and the Lincoln Bedroom; and 10) the Heaven’s 
Gate cult suicide (Boorstein, 1997). Other issues, either related to science and technology or to popular culture, were 
chosen unsystematically and reflect the author’s estimations of major 1997 events or trends.6 
 
Issue or topic w/ number of related New York Times articles for 1997 
  




Themes in Biotechnology-related Coverage, 1970 to 1999 
 
 Percentage of articles
 1970-74 1975-79 1980-84 1985-89 1990-94 1995-99
Applications  
Human cloning 2.9 2.0 2.1 1.2 3.6a 41.6a
Animal Breeding/cloning 0.0 6.0 5.2 9.1 5.2a 25.5a
Plant breeding 0.0 2.0 6.9 6.2 7.2 5.1
Microorganisms 11.8 16.0 8.7 5.3 5.8 0.7
GMO release, plant field test 0.0 0.0 1.7 8.6 1.0 5.1
Gene therapy 11.8 2.0 3.9 2.1 6.5 19.7
Xenotransplantation 2.9 14.0 3.0 0.4 0.8 2.9
In vitro fertilization/reproduction 5.9 6.0 7.3 8.6 5.4 5.1
Pharms/vaccines 0.0 0.0 11.6 17.3 12.9 12.4
DNA research (General) 29.4 64.0 57.1 42.0 35.7a 23.4a
Human inheritance 17.6 6.0 16.3 17.7 23.3a 3.6a
Gene mapping 2.9 0.0 1.5 2.1 4.1 2.5
Diagnosis/predictive medicine 5.9 2.0 7.3 10.7 10.3a 1.5a
Military, defense 0.0 0.0 0.0 0.4 0.0 1.5
Genetic fingerprinting, crime 8.8 2.0 0.9 1.2 5.7a 0.0a
Genetic fingerprinting, other 0.0 0.0 0.0 2.5 3.4a 0.0a
Policy, Politics  and Economics  
Ethical issues 8.8 4.0 6.0 4.5 30.0 31.4
Legal reg. 0.0 32.0 6.4 8.2 3.9a 17.5a
Voluntary  reg. 5.9 8.0 0.0 0.4 9.8 0.0
Econ. prospects 2.9 2.0 21.5 17.3 15.5 13.9
Pat./prop. rights 0.0 0.0 13.7 11.1 7.8 8.0
General biotech policy 0.0 2.0 0.0 5.8 0.5a 8.8a
Insurance issues 0.0 0.0 0.0 0.4 0.8 0.0
Privacy, protection of genetic 0.0 0.0 0.0 0.0 0.5 0.0
Labeling 0.0 0.0 0.0 0.4 1.3 0.0
Eugenics 2.1 2.0 2.1 0.4 1.0 3.6
Education, genetic literacy 0.0 0.0 0.0 1.2 0.3 2.8
Safety and Risks  
General safety and risk 17.6 6.0 16.3 17.7 23.3a 3.6a
Environmental risk 8.8 0.0 1.7 1.6 0.8 0.0
Local community risk 5.9 6.0 1.3 1.6 0.8 0.0
Laboratory workers 2.9 4.0 0.9 0.0 0.0 0.0
Food risk 0.0 0.0 0.0 0.0 3.1 2.9
Biodiversity 5.9 2.0 0.9 3.7 2.8 2.2
Public Reaction  
Public opinion 0.0 6.0 0.9 3.3 2.1a 15.3a
Fear 5.9 2.0 0.0 0.0 0.0 0.0
Other 2.1 0.0 7.3 4.9 5.9 3.6
Number of Articles      34       50    233    243     387     137
 
NOTE: Coders chose up to three themes per article.  Only the most frequently appearing themes are shown here. 
Independent sample T-tests were used to identify significant differences (p≤.05) within specific themes between the 
periods 1990-94 and 1995-99.  Significant differences are indicated by paired superscripts.  Tests for significance 





Frames in Biotechnology-related Coverage, 1970 to 1999 
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 Percentage of Articles
 1970-74 1975-79 1980-84 1985-89 1990-94 1995-99
Progress 58.8 68.0 74.7 81.5 72.9a 39.4a
Econ. prospect 2.9 0.0 13.7 11.1 14.2a 12.4a
Ethical 5.9 4.2 1.7 0.8 2.3a 21.9a
Pub. account. 5.9 0.0 0.0 1.2 0.3 8.0
Pandora’s box 0.0 2.0 0.0 0.4 0.3 2.2
Runaway 2.9 2.0 0.0 0.4 0.3 2.9
Nature/nurture 0.0 0.0 0.0 0.0 0.3 2.9
Globalization 0.0 0.0 0.0 0.0 0.0 1.5
No Frame 23.5 24.0 9.9 4.5 9.6 8.8
Number of Articles           34          50        233        243         387          137
 
NOTE: Coders chose one frame per article. Independent sample T-tests were used to identify significant differences 
(p≤.05) within a specific frame between the periods 1990-94 and 1995-99.  Significant differences are indicated by 
paired superscripts.  Tests for significance across the years 1970 to 1994 were not necessary as data is derived from 
a population of articles, rather than a probability sample. 
 





Tone of Biotechnology-related Coverage, 1970 to 1999 
 
  Percentage of Articles
  1970-74 1975-79 1980-84 1985-89 1990-94 1995-99
Mention Risks  30.3 58.3 40.0 42.0 36.4a 64.2a
Mention Benefits  63.6 85.4 47.4 50.2 57.9a 80.3a
Report Controversy  31.3 44.0 27.5 21.6 21.4a 67.2a
Number of Articles         33           48        232        243    387   137
 
NOTE: Mention of risks and mention of benefits could appear in the same article.  Coders were asked to identify the 
presence or absence of both. Independent sample T-tests were used to identify significant differences (p≤.05) within 
mention of risks, benefits, or controversy between the periods 1990-94 and 1995-99.  Significant differences are 
indicated by paired superscripts.  Tests for significance across the years 1970 to 1994 were not necessary as data is 
derived from a population of articles, rather than a probability sample. 
 




Featured Actors in Biotechnology-Related Coverage, 1970 to 1999 
 
Note:  Coders could choose up to two actors per article.  Only the most frequently appearing actors are shown here. 
Independent sample T-tests were used to identify significant differences (p≤.05) for specific actor between the 
periods 1990-94 and 1995-99.  Significant differences are indicated by paired superscripts.  Tests for significance 
across the years 1970 to 1994 were not necessary as data is derived from a population of articles, rather than a 
probability sample. 
 
 Percentage of Articles 
 1970-74 1975-79 1980-84 1985-89 1990-94 1995-99
None, not applicable 58.9 34.0 50.6 41.5 51.1a 24.1a
Other 5.9 4.0 6.4 5.3 7.0a 0.0a
Government-affiliated   
Federal executive, President 5.9 8.0 3.0 7.8 3.6a 10.9a
EPA 5.9 0.0 1.7 5.8 1.3 0.0
NIH, DHHS 2.9 18.0 11.2 8.6 15.8a 5.1a
USDA 0.0 0.0 2.6 3 1.0 0.7
NSF 2.9 0.0 4.3 9.1 2.8a 0.0a
Patent office 2.9 0.0 3.9 4.1 2.8a 0.0a
Congress 0.0 0.0 0.9 0.4 0.8a 5.1a
Judicial, federal 0.0 2.0 4.3 2.9 6.2a 0.0a
Local or state govt. 0.0 10.0 0.0 0.0 0.0 0.7
Ethics committee 2.9 4.0 0.9 1.2 1.0a 8.8a
Independent review panel 0.0 0.0 0.0 0.4 0.0 0.6
Military 2.9 0.0 0.0 0.0 0.0 0.0
Police 0.0 0.0 1.3 1.6 1.3 0.0
General   
The public 0.0 0.0 0.0 1.2 1.3a 28.5a
The media 5.9 0.0 0.0 0.0 0.5a 17.5a
Science or medicine   
University scientist 44.1 70.0 45.5 39.5 40.5a 20.4a
Institute scientist 0.0 12.0 0.0 7.0 4.9a 29.9a
Scientific organization (AAAS, 5.9 2.0 0.0 0.4 1.8 1.5
Physician 0.0 0.0 2.6 4.9 0.0 8.8
Hospitals 11.8 4.0 4.7 4.9 5.7 3.6
Industry   
Producer 5.9 0.0 32.2 32.9 27.1a 17.5a
Distributor 2.9 0.0 0.0 0.0 0.3 1.5
Industry scientist 0.0 0.0 7.7 0.0 0.0a 2.9a
Other interests   
Religious 0.0 4.0 0.9 0.4 0.8a 4.4a
Consumer 0.0 0.0 0.4 2.5 1.0 0.0
Environmental 2.9 2.0 0.0 1.2 1.6 0.0
Agricultural, farming 0.0 4.0 0.0 2.9 1.3 1.5
Bioethicist 0.0 0.0 0.4 0.4 0.5 2.2
Number of Articles       33            48     232     243      387     137
